hims glp-1 A New Era of Weight Management is Coming to & Hers Hims to begin selling GLP-1
Description
Explore BPS Biosciences solutions for GLP-1R research in diabetes
Novo Nordisk (the maker
A comprehensive search of PubMed, Scopus, CENTRAL, Web of Science, Embase, and ClinicalTrials.gov was conducted to identify relevant studies
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had come to rely on compounded versions is increasingly uncertain.
National Post reports generic semaglutide products could reach Canadian pharmacy shelves by summer 2026 as Health Canada reviews nine applications.
Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases
